Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sigh, the petty bickering of those who stare at monitors hoping the world speeds up. Here is what everyone should be judging the company by this year: the plan of goals and timelines as laid out by the company's President in his Jan letter to shareholders. In it we are to expect the following and anything in addition is bonus, anything that doesn't happen is a negative, but everything that happens on time means we are on the road to probable success.
2016 outlined expectations:
- Q1 - Jan - Mar: Announce new partnerships or collaborations with academic, biotechnology and/or big pharma Done Announced a week later the collaboration with NIH / NCATS (which doesn't mean more announcements cannot follow; but it does mean they have done what they said.) And remember, we found out in one of the PRs, that Kesari has completing experiments on dCellVax and NR2F6 that we hadn't fully known about before. Don't expect a PR about every little detail going on behind the scenes as this is a competitive area and silence can be necessary.
- Q2 - Apr-Jun: dCellVax filing of response to FDA with completed new studies on IND (Studies being conducted at John Wayne Cancer Research Center under direction of Dr. Kesari - no reason to believe this won't be completed as planned)
- New IND submission to FDA for inhibition of NR2F6 in an indication to be determined (RGBP recently announced the filing of various patents and completion of initial studies for NR2F6, so it looks like they are very much on schedule to complete this goal)
- Q3 - Jul-Sep: HemaXellerate Clinical Trial begins
- Identify small molecule inhibitor of NR2F6 I believe this is what Koos was referring to when he said companies filing an IND for this are often valued at half a billion dollars. I'd be happy even if he exaggerated by 100%. But at this point it would be possible for RGBP to have 3 approved INDs (HemaX, dCellVax, new NR2F6) when they file for this 2nd approach of a checkpoint inhibitor for NR2F6, in which case, the value and attraction of big Pharma buyout, licensing and/or collaboration has gone up significantly, wouldn't you agree?
Which means we have all of Q4 - Oct-Dec of 2016 for developments of collaborations, initial trial results to come in and what not, ending 2016 with possibly 3 approved INDs and one in progress, quite the difference from the end of 2013-2014, but building on the value of 2015's first IND approval.
All the rest we are free to dream/speculate and share insights and opinions, but let's at least judge where the company is today based on objective analysis of whether or not they can produce on the plan they have set before us.
And that is why I see the upcoming 3-6 months as possibly the most significant to date in the history of the company for valuation change.
Have you read Lander's open letter on the company status and outlook from January? If not, you should, as every investor or trader should at least read the basics on the company. In his letter, he stated that HemaXellerate trials are projected to begin in the 3rd Qtr or sometime from June 2016 on.
It would, but people acting on insider information within the stock market is fairly commonplace I would say.
Keep in mind that they have 4 days before having to release significant news. I believe the PR on FDA approval came on the 4th day after approval had been received by the company. Given the increase in volume recently, I would not be surprised to see a PR after Thursday close or on Friday morning.
That gives friends and family more time to accumulate before the news.
For anyone who invested in BMSN back during the run of Feb 2013 and has stayed around, the frustration has been palpable through all of 2014 and may have cast a shadow over every good development since.
But to think RGBP at this moment is a duplicate of BMSN and what happened, is to let the past dictate the future even in spite of changes made, which is not objective.
The employees, contracts, incentive milestones given to the Ichims in early 2015 (many/most of which have been met and which outlined a vision of 3 INDs with outside CRO relationships by end of June 2016) have unfolded as dictated between the lines. If anyone fears RGBP is now just a clone of BMSN to entail the same fate, please list for me all the significant parallels that occurred in BMSN before 2015 RGBP changes that are of the same significant nature as outside GLP approved testing of all IND products, multiple new patents (half dozen or more since Jan 2015 I believe), presentations (over half a dozen) at international conferences including upgrades of abstracts to vocal presentations, contracts with NCRI approved cancer institutes for product development, FDA approval of an IND for clinical trials, new contract for collaboration with NIH/NCATS.
If you can provide me with the proof of facts that all or most of these things occurred with BMSN and then went bad, then I will believe RGBP could be headed down the same path. Otherwise, I will have to let the facts dictate what I perceive the future to be.
[If we see another multi hundred thousand shares pickup going into close today, I would expect news soon].
For anyone who invested in BMSN back during the run of Feb 2013 and has stayed around, the frustration has been palpable through all of 2014 and may have cast a shadow over every good development since.
But to think RGBP at this moment is a duplicate of BMSN and what happened is to let the past dictate the future even in spite of changes made which is not objective.
The employees, contracts, incentive milestones given to the Ichims in early 2015 (many/most of which have been met and which outlied a vision of 3 INDs with outside CRO relationships by end of June 2016) have unfolded as dictated between the lines. If anyone fears RGBP is now just a clone of BMSN to entail the same fate, please list for me all the significant parallels that occurred in BMSN before 2015 RGBP changes that are of the same significant nature as outside GLP approved testing of all IND products, multiple new patents (half dozen or more since Jan 2015 I believe), presentations (over half a dozen) at international conferences including upgrades of abstracts to vocal presentations, contracts with NCRI approved cancer institutes for product development, FDA approval of an IND for clinical trials, new contract for collaboration with NIH/NCATS.
If you can provide me with the proof of facts that all or most of these things occurred with BMSN and then went bad, then I will believe RGBP could be headed down the same path. Otherwise, I will have to let the facts dictate what I perceive the future to be.
[If we see another multi hundred thousand shares pickup going into close today, I would expect news soon].
Well, that was a pretty exciting few minutes and a very good sign in my opinion. Things can change very quickly and I think today's sudden volume of someone "BUYING" several hundred thousand shares in a few minutes is a very good indicator for us.
Can't wait for all the developments of the next several weeks.
Nice to see that other than a standing order on the ask, no real selling pressure driving down the PPS throughout the day. Each day gets us closer to news (which so far has been pretty good over the past year).
Funds cleared. Thanks for the shares at .16. Was able to buy 8,000 shares above my targeted number of shares as a result. Lovely. Was worried news would come out before I had the chance.
Thanks. Dilution to raise capital is pretty standard. What hurt us was the form and price of the dilution. Heck, if all the shares were sold at .05/share instead of .025/share, we would have plenty of money in the bank right now.
Past dilution and its method is a red flag and I think Landers knows that he can't bring in large pharma or bigger investors unless the shares faucet for .025 is turned off. The fact that he specifically addressed this in his Jan letter I think is significant and I'll give the benefit of the doubt for now. Frankly if they raised $4M from an investor tomorrow at .08/share, I'd be okay with that because with $4M, we have a good year without further dilution unless even more exciting product pipeline breakthroughs happen.
In my opinion, with funding for initiation of clinical trials in place and no further need/threat of dilution for a year, I think we see the price go up, especially since those extra shares will be restricted for a while.
Koos' share plan did not bid confidence. Any new arrangement that is reasonable, even at 50% discount of current share price is 3x the price Koos was selling for 2 months ago. I would consider that progress.
We should very well have Orphan Drug Designation within next 2 weeks which should put us more likely above .30.
That followed possibly by funding for the clinical trials once ODD is approved will be interesting.
Q2 is what I'm really waiting for. DCellVax testing data resubmitted (maybe even 2nd FDA approval within Q2 along with new IND for NR2F6.
Can't imagine this trading near current price levels if these 4 things take place.
Remember 2014? Waiting for news for months after they had had discussions with FDA about HemaX and DCellVax and we were left in limbo, only to find out the in house testing didn't meet up with FDA criteria months later? In fact, I truly believe RGBP was spun off in March 2015 in anticipation that it would immediately be followed by both HemaX and dCellVax approval and the price (with only 30M float at that time) would sky rocket. The fact all those tests had to be repeated by GLP labs set us back a good 6 months or more and hundreds of thousands of dollars which caused the heavy dilution later in 2015. That was one tough year and some thought the end of the company - claiming it a scam operation.
Then 2015 gave us outside collaborators, multiple international event presentations, upgrades of abstracts to vocal presentations, GLP labs doing the experiments - 1st IND approval. More patents and SAB members.
Now in 2016, we are collaborating with the NIH / NCATS robotic research against thousands of known and approved compounds in a systemic way. We have a nationally recognized cancer research center and head of a cancer department on board researching NR2F6 as well as overseeing final testing of dCellVax (which gives me confidence that data will meet and be accepted by FDA for 2nd IND approval). Plus we have a new President leading the way for fundraising at higher price points. Plus more new patents.
Yeah, has it taken more time than expected, absolutely. Has it been a long and bumpy road to 2016 - affirmative. But does the future look brighter for RGBP - a hundredfold.
Will RGBP be able to get funds? I think with Lander instead of Koos or Caven at the helm, I think we do, especially when you can say we are working with NIH and John Wayne Cancer Research Center. Yep, I think we can. (Keep in mind that Landers is a scientist and when he talks to investors, he can talk the science and answer questions with credentials to back it up.)
We might have to wait for 2017 for uplisting, but we are no longer waiting for good news for months on end. We have the Lander plan and reason to believe by the end of 2016, we could have 3 approved INDs (HemaX, dCellVax and NR2F6) with possibly another 1, 2, or more in the pipeline: DiffronC, additional molecule inhibitor for NR2F6 and/or expansion of dCellVax for gliomas.
This post is for those of you who are new and haven't been around to see the difference and historical transformation that we've seen over the past couple years. And all of these developments have been positive. Since the setbacks of 2014, I don't recall any setbacks at all in 2015 nor any in 2016. The only reality is needing the cash to push things forward and accomplish what couldn't be done in house. Thus the dilution and my only dilution complaint (which is significant) is that Koos way undervalued and sold us short by issuing shares to friends and family at .025-.05/share which was an insult to us. But Landers knows that and addressed it in his letter that that will no longer be happening under his watch. Let it be so.
Stockpimp, you are right that there is not high and constant liquidity in RGBP. In its history the only times of high liquidity were the huge runs of the past which were the results of early catalysts that brought high hopes, and most of those runs were in the parent company BMSN before RGBP existed.
While much of what I say is opinion, it is not only opinion, but based on facts and PRs and SEC filings released by the company. I'm not making it up. If you want opinions based on company insiders, you have to check out illegal sources of information and not depend on this board. For me, my investment in RGBP is high risk reward based on research. To seek investments on illegal insider information is high risk reward of another nature.
As I have posted, I see RGBP, because of low liquidity and a maturing of the company as no longer currently a place for DTs looking for the quick buck. Many who flipped this regularly for 20-30% gains are no longer here as a result.
RGBP currently is a penny stock with a LT huge potential. That said, the timing of significant events outlined in the Jan open letter of Harry Lander points to several important events that should be released to the public over the next Qtr, the timing of which no one can ascertain, which makes RGBP at current PPS a very, very attractive stock to buy if you are willing to wait for those events.
If you want the excitement of day trading and want RGBP to be bouncing up and down on high volume manipulation for quick 20-30% gains, you will be disappointed other than potential days of news events.
The other options are to invest now and wait with money you can keep put or wait until liquidity is consistently high, as when the stock gets uplisted and the larger investment firms can buy in. Of course, at that point you might have to pay from $1-$5/share for a starting position.
I've tried DT and the successes haven't outweighed the losses, so my RGBP investment is LT, now being 3 years and counting (including my first positions in BMSN, the parent company from which I received my first RGBP shares). Tomorrow, when my current deposit is released, I will be adding shares I can play with if I want to, but really looking to sell around .50 or higher as I'll need those funds later this year.
You have to make the decisions to fit your style like the rest of us, but no, don't expect a biotech company to be able to make a earth shaking PR every 2-3 days to continually send the stock higher.
We are off recent lows of .10-.12 and stuck for a while between .13-.15 before that. Now we are beginning a climb up. If you have a base under .20, you are very fortunate and should be rewarded over the next few months. But if you can make 100%-200% or more by DT over the next 6 weeks in another stock, go for it if you want. None of us knows when this will spring, but I'm looking forward to it more and more each day.
Which might very well mean someone hit a milestone and the company needs to sell some shares to cover the bonus.
Nice, thanks Blane.
The more the merrier. Only incorrect statement in article is the mention of expecting word from FDA any day now on dCellVax when we know from Lander's open letter that they expect to file the dCellVax testing response with FDA in Q2 or one month from now at earliest.
Other than that, great summary for newbies to get involved.
Gap closed today. Stay here for another day or two for me to add on shares and then we can relaunch :0)
End of month. First week of new month is generally a buying time for new money. OTC news travels more slowly, so their recent patent filings and statements of preparing a new IND for NR2F6 along with anticipated news back from FDA on HemaX ODD make this a very good time to buy, before the news.
Hey! Quit pushing this up so fast! This is one time I hate it when my predictions might come true. 2 more days; I just need two more days. Actually have the money in the account, but can't buy stocks under $3.00 until 3 days after deposit.
Arrrggghhhh!
Well, I least the shares I want are just add-ons. Looks like 3 years of waiting might just come to fruition within the next 3 months.
Starting to get exciting once again around here.
In recent filing that came out before Lander's open letter, there was another of the most likely "friends and family share plan" $50,000 investment for discounted shares that had not yet been converted to shares. A couple people posted about it, including me.
If those were converted at the former .025/share standard, $50,000 become 2,000,000 shares, which leaves a little over 1M shares unaccounted for. If you search back through contracts, there are probably milestone shares to be released upon approval of HemaX, filing of new patents etc.
We'll find out soon enough, but Lander also indicated that the discounted shares would end during the 1st Qtr, so obviously, there were already commitments for such shares in place when he wrote the letter in Jan. If those shares amount to less than 5M shares collectively, I'm happy with that as the events of the next couple months should significantly increase the price share so that even discounted shares will be above our current trading share price and that will be good for all.
Would be nice if someone could also replace David Suhy with updates on all the new scientific board members. If you need a list, I will compile the list for next week.
Don't drive it up too quickly. Need 2 more days for my tax refund to clear so I can buy a few more shares. .20 or under would be great. I want to be maxed out for the ride.
Thanks LaddyMan, all good to know and reinforce the reasons for our current optimism and confidence things are truly changing with time at RGBP.
Let's also keep in mind that while NR2F6 is truly exciting in its potential and usage and I agree, the current frontrunner of potential income, Dr. Kesari also previously commented that he was performing experiments related to dCellVax with possibility of either expanding current IND or creating new IND to apply dCellVax to brain cancer gliomas, which would be yet another future branch or product line usage.
Other reasons to consider why we might see gains hold well over the next month whereas last year they didn't.
- The "angel investors'" converted shares, which are all free to trade now and were released 1/6 each month over past 6 months, may not be so likely to be traded now that we are within weeks of several important news items (Orphan Drug Status, DCellVax safety testing FDA resubmittal and now new NR2F6 IND). Early on, as these shares were released and good news came out, I think some of them flooded the market to get cash, cover their initial small investment and hold the rest for later since other news was not imminent. Since we know through Koos' interview in La Mesa newspaper that it was all friends and family putting up the money, they will also be aware of the significant scientific progress and possible deals that should greatly increase the value of their remaining shares.
If the angel investors hold their shares until a significant run, the DTs are long gone because price fluctuations are relatively small compared to previous months, we should see continued accumulation.
Expect a significant sell off possibly only AFTER all 3 news items (orphan drug, dCellVax and NR2F6 IND) have been released over the next couple months. Now don't take that to mean there won't be price fluctuation, but as we make gains into 20s, 30s etc, don't sell expecting to buy back at today's prices.
Also, during the past several months we had further fund raising efforts by selling several million shares at .025/share (or issuance thereof). If Lander's is true to his word and has closed that faucet, we won't be seeing the high volume of selling before good news comes out.
I'm pretty confident based on what Lander put in his Jan ltr to shareholders and what we've seen take place in the beginning of 2016 already, means we definitely hit new highs for share price this year and depending on whether they sign either a multi million dollar grant, licensing collaboration or co-development contract with a large pharmaceutical, dollar land is definitely within reach. But it won't all happen tomorrow.
Daily chart shows PPS between 50 and 200 MA, but what is really encouraging about the chart is the accumulation/distribution line that shows the strongest accumulation over time yet. And when accumulation goes against falling stock price, we have neg divergence build up that will cause a pop in price. I know for many charts for OTC stocks are meaningless, but the fact of sustained accumulation for a period of time is a very good indicator here. RGBP Chart
With the sustained accumulation and today's bumping against ST resistance, I think we see prices above .16 by end of week and .20s coming shortly thereafter, probably before I get my tax refund.
Thanks Bulldozer. Appreciate the comments. Been around here for a few years now and have made a lot of bad decisions through the years based on people's self-interested spin and fear.
RGBP has been through a lot of phases and I try to call out both the good and the bad, regardless of the fact I am heavily invested here. It is a risk, no doubt and for many months in 2013-2014, I had to face the reality I might lose it all. But 2015 was a year of major growth and hopeful maturity as a company. Research progression seems to be steady now, the pipeline has grown and we have some very prominent names and entities associated with the company because of its patents and research that weren't on the horizon 2 years ago.
This is no longer the crazy runs and drops on theory stock it once was (cfr. BMSN). While we may have lost the interest of the DT because of that, we are on much better footing for the LT now than we ever were. Not a stock for the impatient, but for those who've hung on or added new positions, 2016-2017 may be the most promising PPS returns of the company's near future if they are successful at what they've outlined in Lander's Jan open letter to shareholders.
Wish I could have bought all my shares at these prices, I'd have over double the shares.
Well, considering that before the end of Q2 2016, RGBP should have Orphan Drug Status for HemaXellerate I with FDA green light for clinical trials of which phase I is only 10 patients. Plus safety testing completed for dCellVax IND possible approval and now testing completed for a third IND regarding not limiting cancer, but actually attacking and killing cancerous cells, I certainly would not say a price of 1.10 to 1.12 is ridiculous, nor is it far fetched.
Keep in mind that Lander was chosen also because of his international connections because of his position associated with setting up a healthcare center overseas.
Now that RGBP has multiple patents and has proven it can move from concept discovery to real results in new testing by outside institutes, how much investment would it take for the price to take off. Very minimal in my opinion.
Orphan Drug status is attractive for investors or pharma companies to develop because of the various tax and gov benefits. Heck, I wouldn't complain if they sold 40M shares to a venture capitalist at .10/share to put 4 million in the bank and assure the launch of all 3 INDs into clinical trials.
With 4 million in the bank and the assurance that family and friends aren't going to get shares at .025/share anymore, I think the PPS would begin to move steadily North even without a big pharma companion.
Add in cooperation at any level with an established pharma name and this easily goes over $1.
AIMO
Man, this is very good news and I got it while away from any trading possibilities. So glad the market is down strong today as I feared I would be buying more share at .18 or over. Glad to pick up some under .16. When my tax return arrives, I'll be happy to pick up more.
This news is especially great because I think Kesari's experiments at John Wayne Cancer Institute are separate from the experiments at the NIH / NCATS program, which means we could have even more significant NR2F6 news before the end of the year.
Previously, I had wondered why the HemaX approved experiments were delayed towards end of year. My theory in light of today's news is that they want to put all effort into new IP, raise the overall price and interest of a partnership and then be able to collaborate with big pharma not just for one product pipeline, but maybe several as they are inter-related.
I'm feeling the best I have in a very long time for the future. If Lander holds true to cutting off the family shares, with all these new concrete and scientific developments with outside reputable entities, RGBP has every chance of launching into the midst of the biotech fray and getting off the OTC as well. Looks like I'll have funds afterall for my daughters college expenses in a couple years if this continues.
This news will eventually get noticed and the PPS I feel now is not going to be falling back. Looking forward to being back into the 20s soon, just hope they send my tax refund soon!
Thanks for posting LaddyMan. I'm not going to make it through the entire reading, but very impressive in the details and thorough application. It took a long time to put the description together, let alone the experimentation and documentation.
Any idea where the experiments were done?
As soon as my tax return comes, have to add some more shares.
The website is describing the IND (which has not yet received approval) which would begin with a 10 patient trial and then expand to the 100 patient trial. Note the last couple of lines that Dr. Kesari is responding to FDA questions. In other company PRs, and even the open letter from Lander in Jan, it is clear that Dr. Kesari is running tests in response to the FDA issues regarding the IND. These tests for dCellVax are expected to be completed in Qtr 2 of 2016 and if sufficient to address all FDA questions and issues, FDA would then approve the IND and allow RGBP to conduct the 10 patient trial.
dCellVax is not in a 10 patient trial. It is confirming data testing with GLP at the John Wayne Cancer Institute under the direction of Dr. Kesari. Tests are estimated to be completed in 2nd Qtr 2016 and then submitted to FDA on behalf of dCellVax IND.
My sense from LII is that there is a lot of trading going on that isn't showing up in real time. Look for a day of after hour T trades showing up in the 10s of thousands.
San Diego - great place. Was just there recently to visit relatives. No doubt there are many companies out there, but the more relationships and IP RGBP establishes, the less chance it goes up in a puff of smoke.
I don't know how many of the cutting edge biotech companies currently have active partnerships with NIH / NCATs or have active relationships with NCA approved institutes like RGBP has been able to establish over this past year. The fact that RGBP over the past year has moved basically from a one man show asking a couple scientists to do some lab work to having full time scientists in house and in cancer research centers under contract and moving multiple pipeline products along with an approved FDA IND for phase 1/2 clinical trials shows that the company has made great strides which should bear fruit exponentially over the course of the coming year.
Is it a guarantee - absolutely not, but our prospects are much better today than they were recently.
There are an awful lot of cutting edge biotech companies with T-cell therapies in their pipelines right now. I hope you all realize that. It's not like RGBP has the only magic cure for cancer. As an investor I really hope that they can get a piece of that pie but realistically I can see that they have very little financial means to make much of what they possess as far as intellectual property. Mainly I hope a lot of you are not in to deep with this company as it could go up in a puff of smoke much more easily than it could become a billion dollar company.
Nope. People buying available market shares brings no income to company and would be a waste of his office - that's a marketing job. His job is to make direct contacts to bring in non-dilutive grants, capital investment and/or pharma collaborations such as licensing, co-development etc. that will fund operations.
His job is not just trying to drive up PPS by having people buy common shares over the market. They need disposable cash.
The earlier post about the possibility of RGBP buying up BMSN was interesting. BMSN has bid of over 600,000,000 shares at .0001. The fact that BMSN has 5B shares O/S as I recall really isn't all that much since at .0001/share, it would only take $500,000 to buy up all shares or $1M at .0002 etc.
It is interesting how active BMSN has been over the past week or so while RGBP has been relatively quiet in volume.
Meach, you have me scratching my head. Lander would not be encouraging people to just go out and buy common shares, as that doesn't bring in any cash flow to the company that it needs.
And we don't have any PRs on new shares being sold to investors (which would be dilutive), so how does the accumulation indicator reflect any action of Lander? Accumulation indicator does mean someone or many are buying up the shares others are selling in a way that is indicating positive future movement for the company, but other than that, I don't see how it relates to anything Lander is and isn't doing regarding ways to bring in cash.
Like others I noted that the discovery was attributed to Dr. Kesari (who is also overseeing the DCellVax safety/data trials.
I don't think the fact that it mentions this discovery to Dr. Kesari means that Christine Ichim is no longer with the company, at least I certainly hope not.
Remember that they have two lines (at least) of investigation going regarding NR2F6 and C. Ichim is pursuing the line of being able to transform cancer stem cells into mature non cancer cells. They have another line of investigation going for creating an oral inhibitor I believe. It makes sense that the two studies would be handled differently and under different people to maximize the greatest progress and therefore I don't think this indicates anything about C. Ichim.
What I see as a positive is that unbeknownst to us, the John Wayne Cancer Institute under Dr. Kesari's leadership is not only performing safety tests for DCellVax IND and looking into expanding dCellVax IND to include gliomas, but it is also performing research related to NR2F6. That's great!
Ditto, and it only takes 10 min to send him an email. And every email is one more reason for him to hold fast to the resolution to make new investors pay more for shares. And the more they raise the stakes for new investors, the better chances for our share values to go up. So I recommend again that we all send one email to Mr. Lander with our views and encouragement: Harry.Lander@regenbiopharma.com
Request to all shareholders for the next week: write Lander an email requesting an end to the .025-.05/share sell off as he indicated in his letter to shareholders. Tell him you hope he comes through in that regard so that we can confidently recommend the company to other investors without fear of being significantly undersold and undervalued.
His email is Harry.Lander@regenbiopharma.com
I just sent off an email responding to his Jan open letter, giving him a little personal insight as to the shareholder's investment and devaluation over the past 3 years and encouraging him to hold up his commitment and create value in the company outside the "friends and family plan" shares.
Maybe if enough of us do that respectfully, he will stand up to Koos and do it. Might as well do something while we want for the testing and science to run its course.
Enjoy the weekend.
In reality, there isn't any pump. We knew there would be selling downward pressure building since the family and friends share plan shares issued last year in March would start releasing in Sept and finish this month around the 19th. 30M shares in total issued that are now mostly free to sell. Now, we can assume that they will want to hold most of the shares until prices increase, but they might be selling a certain percentage both to cover costs and free up money for other investments since by cashing in between .10 and .20 they were still up 300% to 700% by doing so.
With under 500 investors in the stock now, pretty hard to absorb the possible shares being released to market at this point. But one deal or the 2nd Qtr developments (2nd IND approval, dCellVax news...) can relatively quickly absorb all those shares. I don't see much happening until then.
Where they are in reference to other companies, I have no idea, but I fully believe that we will see incrementally effective developments because of the structural changes to the company that started in 2015 and continue today.
The contract with NIH / NCATS to me is huge. NIH I don't think dedicates its research robots to every science project. RGBP had to have something very significant and promising in their research for NIH to sign a research contract with RGBP. This is going to bear fruit in an accelerated way from anything we could have hoped for at the beginning of even 2015.
RGBP having research contract with Dr. Kesari and the John Wayne Cancer Research Center is another significant relationship. If the research data for dCellVax prove positive as expected, the scientific and investor world won't focus on "RGBP discovered "X" in their labs", but instead, it should read, John Wayne Cancer Research Center validates possible cure for breast cancer... Dr. Kesari, head of the JWCRC dept of .... has performed tests showing the possibility of curing breast cancer via...
The fact that future test data and submissions are based on research confirmed/tested/proven in established and highly respected centers, whether CRL (resulting in FDA approved clinical trials), NIH / NCATS, or the JWCRC will go much further in supporting the company and drawing investors than could have been expected had RGBP continued in its pre 2015 ways and means.
The company continues to grow and continues to make steps to act and appear as a true bio company rather than only a one man show. I have more founded hope, more patience and more confidence now than ever. My only concern is the company funding practices at this point and I will await and watch for Lander to change the habits of the past in order to bear greater PPS fruitfulness in the future.
C. Ichim had 18 month incentives and came through to build the company scientific and pipeline products to where they are today. Lander has specific goals, I forget whether tied to incentives or not, but we will watch and await to see his giving positive change to the company's financing practices. The science is going forward, now we need better company management and direction.
Encouraging news today on continuation of progress in new developments on existing pipeline goals. Did anyone else notice that all the citations in the PR refer to articles on the NIH resource website.
The NIH/NCATS is going to be great this year, providing a great partnership for RGBP.
Don't sweat the ticker. Lander's letter points to 2nd Qtr 2016 being the next big time for news and movement. First Qtr 2016 is for announcements of collaborations which might have already been fulfilled with PR on NIH collaborative efforts, though I'm happy if more comes out.
2nd Qtr is when they anticipate to file FDA response for dCellVax (significant news that could bring a 2nd FDA pipeline approval for RGBP, certainly that will help draw both investors and encourage other collaborative offers).
2nd Qtr is also when they plan to file an initial IND for NR2F6 which was very interesting given that they don't anticipate identifying a small molecule inhibitor of NR2F6 until 3rd Qtr. But they announced that they were addressing NR2F6 from 2 distinct angles which means we could have another IND for addressing NR2F6 in the 4th Qtr of 2016.
If all of this happens, RGBP by 2nd Qtr might have 2 FDA approved clinical trials and by end of 2016, 4 approved INDs.
2nd Qtr is when I anticipate the next major price movement for RGBP, but from here on out, good news building on good news will eventually take away all the major doubts.
And as long as the undervalued share selling sprees end (his family and friends should have enough cheapies by now), then sitting back and watching this climb will be a pleasure.
Not worried about the day to day price fluctuations. I'm holding and waiting. Only question is if I get more funds, whether to buy more or not.